1. Home
  2. AFMD vs PMCB Comparison

AFMD vs PMCB Comparison

Compare AFMD & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFMD
  • PMCB
  • Stock Information
  • Founded
  • AFMD 2000
  • PMCB 1996
  • Country
  • AFMD Germany
  • PMCB United States
  • Employees
  • AFMD N/A
  • PMCB N/A
  • Industry
  • AFMD Biotechnology: Pharmaceutical Preparations
  • PMCB Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AFMD Health Care
  • PMCB Health Care
  • Exchange
  • AFMD Nasdaq
  • PMCB Nasdaq
  • Market Cap
  • AFMD 10.2M
  • PMCB 11.4M
  • IPO Year
  • AFMD 2014
  • PMCB N/A
  • Fundamental
  • Price
  • AFMD $0.93
  • PMCB $1.22
  • Analyst Decision
  • AFMD Strong Buy
  • PMCB
  • Analyst Count
  • AFMD 5
  • PMCB 0
  • Target Price
  • AFMD $13.50
  • PMCB N/A
  • AVG Volume (30 Days)
  • AFMD 124.6K
  • PMCB 14.6K
  • Earning Date
  • AFMD 06-11-2025
  • PMCB 03-17-2025
  • Dividend Yield
  • AFMD N/A
  • PMCB N/A
  • EPS Growth
  • AFMD N/A
  • PMCB N/A
  • EPS
  • AFMD N/A
  • PMCB 1.29
  • Revenue
  • AFMD $6,287,085.00
  • PMCB N/A
  • Revenue This Year
  • AFMD N/A
  • PMCB N/A
  • Revenue Next Year
  • AFMD $225.65
  • PMCB N/A
  • P/E Ratio
  • AFMD N/A
  • PMCB $0.94
  • Revenue Growth
  • AFMD N/A
  • PMCB N/A
  • 52 Week Low
  • AFMD $0.52
  • PMCB $1.03
  • 52 Week High
  • AFMD $8.95
  • PMCB $2.42
  • Technical
  • Relative Strength Index (RSI)
  • AFMD 65.06
  • PMCB 43.93
  • Support Level
  • AFMD $0.70
  • PMCB $1.15
  • Resistance Level
  • AFMD $0.85
  • PMCB $1.32
  • Average True Range (ATR)
  • AFMD 0.08
  • PMCB 0.11
  • MACD
  • AFMD 0.04
  • PMCB 0.02
  • Stochastic Oscillator
  • AFMD 89.96
  • PMCB 65.52

About AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: